I have seen many new patients come to my clinic feeling vulnerable and deeply unsettled, seeking help after traumatic experiences with at-home ketamine therapy. They describe feeling “broken open,” overwhelmed by emotions, not knowing what to do in their vulnerable state.
These aren’t isolated incidents. They’re symptoms of an industry that’s treating ketamine like a commodity instead of medicine.
The regulatory disconnect is staggering. While the FDA approved esketamine as SPRAVATO with strict safety protocols, thousands of ketamine clinics and online stores operate in a regulatory gray area with minimal oversight. The FDA warnings about compounded ketamine and at-home use tell the whole story.
We’re conducting a massive uncontrolled experiment on unprotected patients.
The Economics of Exploitation
The numbers reveal everything you need to know about motivation. The ketamine market exploded from $3.41 billion in 2023 to a projected $6.90 billion by 2030, according to market projections.
The growth of the online market comes from somewhere. It comes from removing the expensive parts of medicine.
At-home ketamine companies can reach thousands of patients without medical facilities, trained staff, or monitoring equipment, turning ketamine into a subscription service where a box arrives at your door with a month’s supply. Patients pay monthly fees, get medications shipped to their door, and maybe receive a brief telehealth check-in.
It’s incredibly profitable because they’ve eliminated medical oversight, therapeutic support, safety infrastructure, and a high-quality product.
Meanwhile, legitimate providers like Innerbloom require comprehensive psychiatric evaluation, cardiovascular assessment, and integration therapy with licensed professionals. Our screening process alone takes longer than some discount clinics spend with patients during actual treatment.
When Ketamine Therapy Goes Wrong
The consequences of this regulatory blindness are measurable. Adverse events reported to Poison Centers doubled from 2019 to 2023.
But the numbers don’t capture the psychological trauma.
I’ve treated patients who reported they felt like they were dying during sessions at discount clinics, with staff telling them to “ride it out” and walking away. One patient developed severe anxiety around medical settings. Another described feeling completely abandoned in their most vulnerable psychological state.
Without proper screening, clinics give ketamine to people who shouldn’t receive it. Patients with active psychosis, severe heart conditions, or contraindicated medications slip through basic online questionnaires.
The psychological safety measures are completely absent. SPRAVATO requires healthcare providers trained in managing psychiatric emergencies. We prepare patients extensively for dissociation, help them understand what’s normal, and provide therapeutic support when challenging emotions surface.
With at-home treatment, patients enter altered states of consciousness alone, often without understanding what’s happening to them.
The Pattern We’ve Seen Before
This follows a predictable healthcare pattern. Breakthrough therapies get commercialized faster than they can be properly regulated.
OxyContin was marketed as a breakthrough pain treatment. Medical marijuana dispensaries operated with minimal oversight while patients became guinea pigs for dosing methods.
Ketamine’s speed and scale make it particularly concerning. With opioids, problems emerged over years. With ketamine, we’re seeing issues in real-time because companies scale so aggressively using venture capital funding.
The pattern stays the same. Innovation outpaces regulation, commercial interests drive expansion, and vulnerable patients bear the risks.
The difference with ketamine involves people in mental health crises at their most desperate point. When someone with treatment-resistant depression sees ads promising relief at home for a fraction of clinical costs, they’re thinking about feeling better, not safety protocols.
Questions That Reveal Everything
For those who are still interested in using at-home ketamine despite the risks, I tell them to ask specific questions that legitimate providers answer confidently, while questionable ones dodge or deflect.
Ask about their medical screening process before your first treatment. Legitimate providers describe comprehensive medical history review, psychiatric evaluation, medication interaction screening, and cardiovascular assessment.
Ask who will be present during treatment and their qualifications. You want a licensed physician or nurse practitioner on-site, not a “ketamine technician” or wellness coach. At Innerbloom, I’m present for every treatment because ketamine remains an anesthetic requiring medical oversight.
Ask what happens if you have a medical emergency during treatment. Legitimate clinics have emergency protocols, medical equipment, and trained staff. If they seem unprepared for this question, please walk away.
Ask about integration support. How do they help you process and apply insights from sessions? If they can’t explain how ketamine creates windows for psychological work, they’re just getting you high, not treating you.
The biggest tell is how they respond to these questions. Real medical providers welcome detailed questions about safety and protocols. Ketamine mills get defensive or redirect you to pricing and scheduling.
The Path Forward
We need immediate regulatory action before this becomes another opioid-level disaster.
The FDA must close the compounding pharmacy loophole that allows at-home companies to operate outside a proper safety framework. If ketamine treats psychiatric conditions, it should fall under the same rigorous oversight.
We need mandatory certification for ketamine providers, similar to SPRAVATO facilities. Any clinic offering ketamine therapy should demonstrate proper medical oversight, emergency protocols, and integration support.
Professional medical organizations need clear practice guidelines about safe ketamine therapy. Right now, there’s far too much variability in provider approaches.
But the biggest change needs patient education. People must understand that cheaper and more convenient options do not mean better psychiatric treatment. We need public awareness campaigns about unregulated ketamine risks.
The window is closing fast. Every month, these unregulated companies scale up, creating more potential for harm. We can see this crisis coming.
We just need the regulatory will to stop it before it’s too late.
About the Author
Dr. Ray Rivas, a former general and trauma surgeon with over a decade of experience utilizing ketamine, became a ketamine therapy specialist to treat mental health and pain after witnessing its profound impact on his hospital trauma patients and his own mental health. As the founder and medical director of Innerbloom Ketamine Therapy in San Luis Obispo, California, Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.